	US 12,065,446 B2
	Inhibitors of Bruton's tyrosine kinase and method of their use
Nidhi Arora, San Diego, CA (US); Genesis M. Bacani, San Diego, CA (US); Joseph Kent Barbay, Flourtown, PA (US); Scott D. Bembenek, San Diego, CA (US); Charlotte Pooley Deckhut, San Diego, CA (US); James P. Edwards, Ambler, PA (US); Brahmananda Ghosh, Spring House, PA (US); Kevin D. Kreutter, Arlington, MA (US); Mark S. Tichenor, San Diego, CA (US); Jennifer D. Venable, Solana Beach, CA (US); Jianmei Wei, San Diego, CA (US); and John J. M. Wiener, La Jolla, CA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed on Mar. 25, 2022, as Appl. No. 17/705,225.
Application 17/705,225 is a continuation of application No. 15/931,437, filed on May 13, 2020, granted, now 11,319,329.
Application 15/931,437 is a continuation of application No. 15/374,905, filed on Dec. 9, 2016, granted, now 10,717,745.
Claims priority of provisional application 62/265,836, filed on Dec. 10, 2015.
Prior Publication US 2023/0097422 A1, Mar. 30, 2023
Int. Cl. C07D 495/16 (2006.01); C07D 519/00 (2006.01)

CPC C07D 495/16 (2013.01) [C07D 519/00 (2013.01)]

4 Claims

1. A method of treating cancer in a subject comprising administering to the subject a compound,

N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(S)-(6-isobutyl-4-methylpyridin-3-yl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8-triazaacenaphthylene-2-carboxamide, and any isotopic variant or a pharmaceutically acceptable salt thereof.